- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
When a pregnant woman is diagnosed with breast cancer, treatment must consider the woman’s cancer but also the potential risks to the fetus.
BCRF-Supported Study Finds Nigerian Women at Higher-Risk for Late-Stage and Inherited Breast Cancers
BCRF investigators conducted a 20-year long study to determine why breast cancer incidences have increased in Nigeria
A multi-institutional team of scientists are making promising discoveries about the tumor microenvironment that could yield breakthroughs in breast cancer early detection and treatment.
The groundbreaking TAILORx Study is the largest trial of its kind with over 10,000 patients enrolled in 6 countries.
BCRF investigators discuss strategies to improve treatment in ER-positive breast cancer at the annual meeting of the American Association for Cancer Research.
BCRF investigator Kornelia Polyak explains how tumors become a mixture of cells and how this relates to metastatic breast cancer.
BCRF investigators Fabrice André, Sarat Chandalapaty, and Nikhil Wagle address the challenges of resistance to CDK4/6 inhibitors.
BCRF Researchers Identify New Drivers of Drug Resistance in Metastatic Estrogen Receptor-Positive Breast Cancer
ESR1 gene fusions drive resistance to endocrine therapies in some tumors and are a new potential target to develop drugs to overcome resistance
BCRF investigators report DNA modifications in breast cancer risk genes may be a result of combined genetic and environmental causes.
BCRF investigators join forces to launch BFOR, an innovative study offering genetic testing for women and men of Ashkenazi Jewish ancestry.